NCT01721317 - Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2012

Primary Completion Date

June 20, 2013

Study Completion Date

June 20, 2013

Conditions

Seizures

Interventions

DRUG

Ezogabine/Retigabine IR

Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.

DRUG

Placebo

Matching placebo will be available

Trial Locations (11)

10676

GSK Investigational Site, Athens

20817

GSK Investigational Site, Bethesda

33952

GSK Investigational Site, Port Charlotte

55422

GSK Investigational Site, Golden Valley

57010

GSK Investigational Site, Thessaloniki

76017

GSK Investigational Site, Arlington

77339

GSK Investigational Site, Kingwood

80907

GSK Investigational Site, Colorado Springs

90404

GSK Investigational Site, Santa Monica

93710

GSK Investigational Site, Fresno

97504

GSK Investigational Site, Medford